Search hospitals > Alabama > Mobile
University of South Alabama Mitchell Cancer Institute
Claim this profileMobile, Alabama 36688
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Ovarian Cancer
Conducts research for Relapse
Conducts research for Cervical Adenocarcinoma
130 reported clinical trials
13 medical researchers
Summary
University of South Alabama Mitchell Cancer Institute is a medical facility located in Mobile, Alabama. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Ovarian Cancer, Relapse, Cervical Adenocarcinoma and other specialties. University of South Alabama Mitchell Cancer Institute is involved with conducting 130 clinical trials across 254 conditions. There are 13 research doctors associated with this hospital, such as Moh'd Khushman, Ahmed Abdalla, Teja Poosarla, MD, and Jennifer Scalici,, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Moh'd KhushmanWashington University School of Medicine2 years of reported clinical research
Studies Pancreatic Cancer
Studies Colorectal Cancer
8 reported clinical trials
17 drugs studied
Ahmed AbdallaUniversity of South Alabama Mitchell Cancer Institute1 year of reported clinical research
Studies Cancer
Studies Uterine Tumors
8 reported clinical trials
29 drugs studied
Teja Poosarla, MDUniversity of South Alabama Mitchell Cancer Institute9 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
5 reported clinical trials
15 drugs studied
Jennifer Scalici,, MDUSA Mitchell Cancer Institute2 years of reported clinical research
Studies Ovarian Cancer
Studies Peritoneal Malignancies
5 reported clinical trials
8 drugs studied
Clinical Trials running at University of South Alabama Mitchell Cancer Institute
Cancer
Ovarian Cancer
Gallbladder Cancer
Pancreatic Cancer
Endometrial Cancer
Bile Duct Cancer
Non-Small Cell Lung Cancer
Solid Tumors
Rectal Cancer
Relapse
Ipatasertib + Chemotherapy
for Cancer
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2
Neratinib or Neratinib + Palbociclib
for Cancer
This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.
Recruiting1 award Phase 2
Palbociclib + Binimetinib
for Pancreatic Cancer
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.
Recruiting1 award Phase 210 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of South Alabama Mitchell Cancer Institute?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.